Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 00168-0003-15
triamcinolone acetonide .25 mg/g Cream — NDC 00168-0003-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

triamcinolone acetonide .25 mg/g Cream — NDC 0168-0003-15 (Billing 00168-0003-15)

by E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of triamcinolone acetonide .25 mg/g Cream from E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, marketed since Mar 1978 and currently FDA-listed; retail pharmacies pay about $0.1198 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00168-0003-15
🏷️ FDA NDC (as labeled) 0168-0003-15 billing pads the labeler segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.1198 NADAC Per package$1.80 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.2996/unit · Part D plans $0.1230/unit — full pricing hub ↓
Main listing for product 0168-0003 · Also comes in: 80 g 0168-0003-80
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0168-0003-15 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0168 labeler · 0003 product · 15 package
Package marketed since
Mar 9, 1978
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC)
0301680004150, 0301680003153, 0301680002156
Medicaid fills, this package
29,367 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Past resolved recalls for this product (1)
Class II · Apr 13, 2022 · Terminated — cGMP deviations: Temperature abuse (Mckesson Medical-Surgical Inc. Corporate Office) · FDA recall D-1106-2022

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0168-0003-15
Product NDC 0168-0003
11-digit billing NDC 00168000315
NCPDP billing unit GM — per gram (weight)
RxCUI 1014314, 1085644, 1085686
UNII F446C597KA
UPC 0301680004150, 0301680003153, 0301680002156
Application # ANDA085692
SPL Set ID 92a1ded0-8e1a-4994-9c8a-89e84fc85c94
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1978-03-09
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90550085103705
GPI class Triamcinolone Acetonide
GCN Seq No 007593
GCN 31231
HICL code 002891
Ingredient (HICL) Triamcinolone Acetonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name TRIAMCINOLONE 0.025% CREAM
FDB brand name Triamcinolone Acetonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007593
  • GCN: 31231
  • GPI-14 (Medi-Span): 90550085103705
  • HICL (First Databank): 002891
  • AHFS class code: 48:10.08.00
  • RxCUI (RxNorm): 1014314
Why two NDCs? The FDA registers this code as 0168-0003-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00168-0003-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TRIAMCINOLONE 0.025% CREAM Ingredient Triamcinolone Acetonide
📖 What it is MedlinePlus · NLM

Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It relieves the redness, swelling and itching of skin conditions that respond to steroids. The ointment can also be used under dressings for psoriasis or other stubborn skin proble...
  • Use a thin film on the affected area, usually two to three times a day for the 0.1% ointment. More is not better. Follow your prescriber's directions and the label.
  • Only if your prescriber tells you to. Airtight dressings greatly increase how much medicine gets absorbed. If the skin shows signs of infection, stop the dressings and call your do...
  • Should I cover the area with a bandage or wrap?
📖 Read our full Triamcinolone Topical guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.120 $1.80 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.2996 $4.49 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.1230 $1.85 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.170 $0.115
▼ Down 24% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00168-0003-15 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.1198 / g $1.80 1978-03-09 — Active
00168-0003-80 0168-0003-80 1 TUBE in 1 CARTON / 80 g in 1 TUBE $0.0532 / g $4.26 1978-03-09 — Active

Per g, this pack runs about 125% above the cheapest pack (NDC 00168-0003-80, $0.0532 vs $0.1198 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 64% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of triamcinolone acetonide .25 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide .25 mg/g 45802-0063-05 Padagis 454 g $0.035 AT Availability likely save 71%
Triamcinolone Acetonide .25 mg/g 45802-0054-05 Padagis 454 g $0.047 AT Availability likely save 61%
Triamcinolone Acetonide .25 mg/g 00168-0005-80 E. 80 g $0.074 AT Availability likely save 38%
triamcinolone acetonide .25 mg/gthis 00168-0003-15 E. 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 00713-0226-15 Cosette 1 tube $0.120 AT Discontinued —
Triamcinolone Acetonide .25 mg/g 16714-0985-01 NorthStar 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 33342-0327-15 Macleods 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 67877-0317-15 Ascend 15 g $0.120 AT Availability likely —
Triamcinolone acetonide .25 mg/g 33342-0331-15 Macleods 1 tube $0.239 AT Availability likely +100%
Triamcinolone Acetonide .25 mg/g 00713-0229-15 Cosette 1 tube $0.239 AT Availability likely +100%
Triamcinolone acetonide .25 mg/g 16714-0267-01 NorthStar 1 tube $0.239 AT Availability likely +100%
Triderm .25 mg/g 00316-0165-15 Crown 1 tube — AT FDA listed —
triamcinolone acetonide .25 mg/g 50090-0293-01 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-2658-00 A-S 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3704-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63187-0214-80 Proficient 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8782-01 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8784-01 Bryant 454 g — AT FDA listed —
Triamcinolone acetonide .25 mg/g 68071-2361-01 NuCare 15 g — AT FDA listed —
triamcinolone acetonide .25 mg/g 68788-8515-08 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-8899-01 Preferred 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 71335-2870-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-1835-02 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2334-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0347-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0360-80 Asclemed 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8841-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2335-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3802-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-4148-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-0362-00 A-S 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1978
On the market since
Mar 1978
📍
2026
Currently FDA-listed
48 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Triamcinolone Topical inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 8CRQ2TH63M
    Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII 506T60A25R
    Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerE. Fougera & Co. a division of Fougera Pharmaceuticals, LLC
Application holderFOUGERA PHARMACEUTICALS INC
FDA applicationANDA085692 (ANDA)
Labeler code00168
First marketedMar 1978
Product typeHuman Prescription Drug
Portfolio33 products on file

More NDCs from E. Fougera & Co. a division of Fougera Pharmaceu... labeler code 00168

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 73 words ▾

DOSAGE AND ADMINISTRATION: Apply to the affected area as a thin film as follows: Triamcinolone Acetonide Cream USP, 0.025% two to four times daily; Triamcinolone Acetonide Cream USP, 0.1% and 0.5% two or three times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 60 words ▾

ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

🤰 Pregnancy 92 words ▾

Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 114 words ▾

Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

🧬 Clinical Pharmacology 192 words ▾

CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 83 words ▾

HOW SUPPLIED: Triamcinolone Acetonide Cream USP, 0.025% Triamcinolone Acetonide Cream USP, 0.1% 15 gram tubes NDC 0168-0003-15 15 gram tubes NDC 0168-0004-15 80 gram tubes NDC 0168-0003-80 80 gram tubes NDC 0168-0004-80 1 Lb jars NDC 0168-0004-16 Triamcinolone Acetonide Cream USP, 0.5% 15 gram tubes NDC 0168-0002-15. Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat.

Protect from freezing. Fougera PHARMACEUTICALS INC. E.

FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville New York 11747 I20215G/IF20215G R09/11 #227 46165001A R06/15 #65

📋 Description 128 words ▾

DESCRIPTION: Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50. CAS 76-25-5. Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. chemstructure

💬 Information for Patients 128 words ▾

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.

It is for external use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS: General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate anti-fungal or antibacterial agent should be instituted.

If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1.

This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3.

The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4. Patients should report any signs of local adverse reactions especially under occlusive dressing.

5. Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests: The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test; ACTH stimulation test.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.

The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.

Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric Use: Pediatric patients may demonstrate greater susceptibili… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 58 words ▾

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

🧬 Pharmacokinetics 132 words ▾

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

📄 Package Label / Principal Display Panel ~1 min read ▾

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 15g CONTAINER NDC 0168-0003-15 FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.025% Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT 15 grams 005percentlabel.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 15g CARTON NDC 0168-0003-15 Rx only FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.025% WARNING: Keep out of reach of children. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT 15 grams 0025percentcartonserialized

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.1% 15g CONTAINER NDC 0168-0004-15 FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.1% Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT 15 grams triamcream15gmtube

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.1% 15g CARTON NDC 0168-0004-15 Rx only FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.1% WARNING: Keep out of reach of children. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT 15 grams 01percentcartonserialized

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.5% 15g CONTAINER NDC 0168-0002-15 FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.5% Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE . NET WT 15 grams 05percentlabel

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.5% 15g CARTON NDC 0168-0002-15 Rx only FOUGERA ® TRIAMCINOLONE ACETONIDE CREAM USP, 0.5% WARNING: Keep out of reach of children. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT 15 grams 05percentcartonserialized

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
29.4K
Units reimbursed last 4 qtrs
829.7K
Gross reimbursed last 4 qtrs
$248.6K
Avg / prescription
$8.46
Avg / unit
$0.2996
Latest quarter Q1 2026
6.3KRx
Medicaid pays / g
$0.2996
gross reimbursed
vs
NADAC / g
$0.1198
acquisition cost
=
Spread
+$0.1798
+150% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 10,446 Rx Managed care · 18,921 Rx
State Medicaid map
Alaska: no data reported AK Maine: 2,715 units · 195 per 100k residents ME Washington: 8,550 units · 109 per 100k residents WA Idaho: 795 units · 40.5 per 100k residents ID Montana: 1,995 units · 176 per 100k residents MT North Dakota: 180 units · 23.0 per 100k residents ND Minnesota: 7,279 units · 127 per 100k residents MN Wisconsin: 6,210 units · 105 per 100k residents WI Michigan: 46,938 units · 468 per 100k residents MI New York: 161,385 units · 825 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 4,770 units · 113 per 100k residents OR Nevada: 2,040 units · 63.9 per 100k residents NV Wyoming: no data reported WY South Dakota: 330 units · 35.9 per 100k residents SD Iowa: 5,025 units · 157 per 100k residents IA Illinois: 20,465 units · 163 per 100k residents IL Indiana: 70,950 units · 1,034 per 100k residents IN Ohio: 48,835 units · 414 per 100k residents OH Pennsylvania: 107,065 units · 826 per 100k residents PA New Jersey: 45,370 units · 488 per 100k residents NJ Massachusetts: 6,752 units · 96.4 per 100k residents MA California: 63,709 units · 164 per 100k residents CA Utah: 615 units · 18.0 per 100k residents UT Colorado: 4,135 units · 70.3 per 100k residents CO Nebraska: 1,740 units · 88.0 per 100k residents NE Missouri: 15,529 units · 251 per 100k residents MO Kentucky: 7,800 units · 172 per 100k residents KY West Virginia: 8,565 units · 484 per 100k residents WV Virginia: 12,390 units · 142 per 100k residents VA Maryland: 45,805 units · 741 per 100k residents MD Connecticut: 3,945 units · 109 per 100k residents CT Rhode Island: 480 units · 43.8 per 100k residents RI Arizona: 2,430 units · 32.7 per 100k residents AZ New Mexico: 4,035 units · 191 per 100k residents NM Kansas: 5,745 units · 195 per 100k residents KS Arkansas: 1,185 units · 38.6 per 100k residents AR Tennessee: 10,365 units · 145 per 100k residents TN North Carolina: 9,075 units · 83.8 per 100k residents NC South Carolina: 3,570 units · 66.4 per 100k residents SC Delaware: 3,165 units · 307 per 100k residents DE Oklahoma: 7,680 units · 189 per 100k residents OK Louisiana: 4,570 units · 99.9 per 100k residents LA Mississippi: 1,755 units · 59.7 per 100k residents MS Alabama: 8,300 units · 162 per 100k residents AL Georgia: 12,050 units · 109 per 100k residents GA D.C.: 4,015 units · 591 per 100k residents DC Hawaii: no data reported HI Texas: 19,845 units · 65.1 per 100k residents TX Florida: 19,545 units · 86.4 per 100k residents FL
Units reimbursed · per 100k residents
18.01,034
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Indiana 1,034 /100k
2 Pennsylvania 826 /100k
3 New York 825 /100k
4 Maryland 741 /100k
5 D.C. 591 /100k
6 New Jersey 488 /100k
7 West Virginia 484 /100k
8 Michigan 468 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page00168-0003-15 29,367 Rx · $248,567
1 tube00168-0003-80 16,184 Rx · $180,669
Drug total (last 4 qtrs): 45,551 Rx · 2,149,236 units · $429,236 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00168-0002-15 · E. 00168-0004-15 · E. →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.